- Republican Wins Virginia in Test of Obama's Clout
- German Opel Workers Bitter After GM Shock
- Look Ahead: Market Taking Its Cues From Fed Statement
- Bailed-Out Banks Preparing Pay Bonanza: Study
- World Bank Raises East Asia Growth Forecast
- Berkshire's 15 Biggest Stock Holdings
- Buffett Needed No Bankers for Burlington Deal
- Oracle-Sun Micro Deal May Be Rejected by EU: Report
- Toyota to Pull Out of F1, Raise Output: Report
- Final World Series Games Big Money Makers
- Best Buy To Embed Digital Download Platform on Devices
- Options Trader Targets Precious Metal Surge
- October Shows Auto Rebound Will Be Slow
- The Silencing of Paul Volcker?
- CNBC Transcript: Warren Buffett Explains His Railroad 'All-In Bet' on America
- CIT's Retail Impact?
- M&A: Signs of Strength?
- Crescenzi: Fed Exit Best As Process, Not Event
MOST SHARED
- US Commercial Property Up in Third Quarter: Index
- Lack of Paid Sick Days May Worsen Flu Pandemic
- AT&T Sues Verizon Over 'Misleading' Wireless Ads
- The World's Most Secretive Tax Havens
- Ford CEO: We're on a Steady Trajectory of Growth Now
- US Economic Growth Could Accelerate After Strong Reports
- Pending Home Sales Rise for Eighth Straight Month
- CIT Group Files for Bankruptcy Protection
- Israel: Leader of Business Innovation
- PepsiCo misplaces letter, faces $1.26 bln judgment
Text Size 
U.S. drugmaker Merck & Co's $41.1 billion takeover of smaller rival Schering-Plough won approval from European Union antitrust regulators Friday.
The takeover, structured by Merck as a reverse merger, followed a long-standing joint venture between Merck and Schering-Plough that sells the cholesterol fighters Vytorin and Zetia.
"The proposed transaction would not significantly impede effective competition in the European economic area or any substantial part of it," the European Commission, executive arm of the 27-country EU, said in a statement.
Merck has agreed to sell its half of the Merial animal health business to Sanofi-Aventis its French partner in that joint venture, for $4 billion in order to meet antitrust requirements for the Schering-Plough takeover.
 |
AP |
The deal still needs U.S. antitrust approval. The companies continue to expect the transaction to close in the fourth quarter.
Merck [MRK
Loading...
()
] has said it hopes cost cuts from the merger and a number of promising products from Schering-Plough [SGP
Loading...
()
] will improve its profit outlook.
The merged companies will cut 15 percent of their combined workforce, with most job losses to take place outside the United States.
Print
Email
- These four sectors will be the next to lead the market.
- These executives got the largest pay packages of the last 10 years.
- People who are scared of flying can now press a button on their iPhone to help them deal with their panic.
- A Harvard professor’s unusual confectionary is blowing away chocolatiers in Paris.
- How much would you pay for a motorized La-Z-Boy? An eBay auction for a police-confiscated 'DWI' chair is fetching high dollars.
- What you need to know.
Data is a real-time snapshot *Data is delayed at least 15 minutes